Literature DB >> 17483689

The etiopathogenesis of Parkinson disease and suggestions for future research. Part II.

Irene Litvan1, Marie-Francoise Chesselet, Thomas Gasser, Donato A Di Monte, Davis Parker, Theo Hagg, John Hardy, Peter Jenner, Richard H Myers, Donald Price, Mark Hallett, William J Langston, Anthony E Lang, Glenda Halliday, Walter Rocca, Charles Duyckaerts, Dennis W Dickson, Yoav Ben-Shlomo, Christopher G Goetz, Eldad Melamed.   

Abstract

We are at a critical juncture in our knowledge of the etiology and pathogenesis of Parkinson disease (PD). It is clear that PD is not a single entity simply resulting from a dopaminergic deficit; rather it is most likely caused by a combination of genetic and environmental factors. Although there is extensive new information on the etiology and pathogenesis of PD, which may advance its treatment, new syntheses of this information are needed. The second part of this two-part, state-of-the-art review by leaders in PD research critically examines the research field to identify areas for which new knowledge and ideas might be helpful for treatment purposes. Topics reviewed in Part II are genetics, animal models, and oxidative stress.

Entities:  

Mesh:

Year:  2007        PMID: 17483689     DOI: 10.1097/nen.0b013e318053716a

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  14 in total

Review 1.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

2.  Recovery of hypothalamic tuberoinfundibular dopamine neurons from acute toxicant exposure is dependent upon protein synthesis and associated with an increase in parkin and ubiquitin carboxy-terminal hydrolase-L1 expression.

Authors:  Matthew Benskey; Bahareh Behrouz; Johan Sunryd; Samuel S Pappas; Seung-Hoon Baek; Marianne Huebner; Keith J Lookingland; John L Goudreau
Journal:  Neurotoxicology       Date:  2012-02-09       Impact factor: 4.294

3.  Cerebrospinal Fluid C-Reactive Protein in Parkinson's Disease: Associations with Motor and Non-motor Symptoms.

Authors:  Hossein Sanjari Moghaddam; Zahra Valitabar; Amir Ashraf-Ganjouei; Mahtab Mojtahed Zadeh; Farzaneh Ghazi Sherbaf; Mohammad Hadi Aarabi
Journal:  Neuromolecular Med       Date:  2018-07-06       Impact factor: 3.843

4.  Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson's disease?

Authors:  Sharon Hassin-Baer; Oren S Cohen; Eli Vakil; Noa Molshazki; Ben-Ami Sela; Zeev Nitsan; Joab Chapman; David Tanne
Journal:  J Neural Transm (Vienna)       Date:  2010-12-16       Impact factor: 3.575

5.  The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.

Authors:  Matthew J Benskey; Fredric P Manfredsson; Keith J Lookingland; John L Goudreau
Journal:  Neurotoxicology       Date:  2014-11-20       Impact factor: 4.294

Review 6.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

Review 7.  Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration.

Authors:  Juan A Orellana; Pablo J Sáez; Kenji F Shoji; Kurt A Schalper; Nicolás Palacios-Prado; Victoria Velarde; Christian Giaume; Michael V L Bennett; Juan C Sáez
Journal:  Antioxid Redox Signal       Date:  2009-02       Impact factor: 8.401

8.  Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype.

Authors:  Irit Rappley; David S Myers; Stephen B Milne; Pavlina T Ivanova; Matthew J Lavoie; H Alex Brown; Dennis J Selkoe
Journal:  J Neurochem       Date:  2009-07-17       Impact factor: 5.372

9.  Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease.

Authors:  Katrin Beyer; Montserrat Domingo-Sàbat; Jordi Humbert; Cristina Carrato; Isidro Ferrer; Aurelio Ariza
Journal:  Neurogenetics       Date:  2008-03-12       Impact factor: 2.660

Review 10.  In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?

Authors:  Marie-Francoise Chesselet
Journal:  Exp Neurol       Date:  2007-08-23       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.